MedPath

安徽长江药业有限公司

Ownership
-
Established
2001-12-25
Employees
-
Market Cap
-
Website
www.changjiangpharma.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

168

NMPA:168

Drug Approvals

Phenylephrine Hydrochloride Injection

Product Name
盐酸去氧肾上腺素注射液
Approval Number
国药准字H20254136
Approval Date
May 13, 2025
NMPA

Haloperidol Injection

Product Name
氟哌啶醇注射液
Approval Number
国药准字H20253845
Approval Date
Apr 8, 2025
NMPA

Bupivacaine Hydrochloride Injection

Product Name
盐酸布比卡因注射液
Approval Number
国药准字H20258019
Approval Date
Feb 19, 2025
NMPA

Metoclopramide Hydrochloride Injection

Product Name
盐酸甲氧氯普胺注射液
Approval Number
国药准字H20249646
Approval Date
Dec 1, 2024
NMPA

Diprophylline Injection

Product Name
二羟丙茶碱注射液
Approval Number
国药准字H20249517
Approval Date
Dec 1, 2024
NMPA

Peramivir Injection

Product Name
帕拉米韦注射液
Approval Number
国药准字H20244617
Approval Date
Aug 5, 2024
NMPA

Dobutamine Hydrochloride Injection

Product Name
盐酸多巴酚丁胺注射液
Approval Number
国药准字H20247162
Approval Date
Jul 12, 2024
NMPA

Dexamethasone Sodium Phosphate Injection

Product Name
地塞米松磷酸钠注射液
Approval Number
国药准字H20247152
Approval Date
Jul 8, 2024
NMPA

Dopamine Hydrochloride Injection

Product Name
盐酸多巴胺注射液
Approval Number
国药准字H20234402
Approval Date
Oct 27, 2023
NMPA

Dopamine Hydrochloride Injection

Product Name
盐酸多巴胺注射液
Approval Number
国药准字H20234401
Approval Date
Oct 27, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 17
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.